Novo Nordisk has invested 6.4bn Brazilian reais ($1.09bn) to expand its facility in Brazil as the company ramps up efforts to increase production of its flagship glucagon-like peptide 1 receptor ...

As a pioneer in diabetes care, Novo Nordisk NVO claims 34% of the USD 80 billion-plus diabetes treatment market and roughly half of the insulin market, itself worth more than USD 15 billion.

Novo Nordisk (NVO) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in ...

While much of the recent GLP-1 saga has been written in the U.S., Novo Nordisk continues to expand its semaglutide empire across the globe and make inroads into large markets like Brazil.

Novo Nordisk A/S has a fifty-two week low of $60.61 and a fifty-two week high of $148.15. The company has a market capitalization of $285.03 billion, a price-to-earnings ratio of 19.31, a P/E/G ...

SAO PAULO, April 7 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab, the producer of Ozempic, Wegovy and other medications, will invest 6.4 billion reais ($1.09 billion) in Brazil to boost ...

In its fourth quarter 2024 investor letter, Artisan Global Opportunities Fund emphasized stocks such as Novo Nordisk A/S (NYSE:NVO). Novo Nordisk A/S (NYSE:NVO) engages in the research and ...

Claim your 7-day free trial now. Novo Nordisk A/S NVO on Saturday presented the full results from the Phase 3b STRIDE peripheral artery disease (PAD) outcomes trial. The study evaluated the once ...

Novo Nordisk has experienced a 50% drop due to potential tariffs and recent clinical trial results but remains strong in diabetes treatment, insulin, and GLP-1 products. I outline the bull case ...

Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets, valued at more than $100 billion. Each of them has advantages, as well as dark spots in the pipeline of ...

Danish drugmaker Novo Nordisk has been dethroned by German software giant SAP as Europe’s most valuable company. SAP has soared some 40 per cent over the last year as investors celebrated its ...

Based on SOUL findings, Novo Nordisk submitted a label extension application for Rybelsus ® for CV event risk reduction to the US FDA and EMA. Bagsværd, Denmark, 29 March 2025 - Novo Nordisk ...